Suggested remit: To appraise the clinical and cost effectiveness of pirtobrutinib within its marketing authorisation for relapsed or refractory mantle cell lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 3975

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
05 October 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
03 August 2022 - 01 September 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
03 August 2022 In progress. Scoping commenced
31 March 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma after a BTK inhibitor. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
24 November 2021 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual